Ainos, Inc. AIMDW
Nov 4, 2026, 2:36 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 1.58M
- Revenue (ttm)
- 40.63K
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 700
- Open
- 0.17
- Previous close
- 0.0579
- Day's range
- 0.0391 – 0.0462
- 52-week range
- 0.0462 – 0.0462
- Beta
- 1.41
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 621.86K
- Total cash
- 5.16M
- Total debt
- 12.27M
- Return on equity
- -70.60%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About Ainos, Inc.
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- ainos.com
News
Ainos Announces AI Nose Platform Hits Over 3B Chemical Data Points 
Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Drop in Short Interest 
Ainos Completes Required Data Delivery And Technology Transfer Under Its VELDONA License Deal For $600K Initial License Payment 
Ainos Receives Three New Japanese Patents For Its AI Nose Technologies 
Ainos’ AI Nose Platform Surpasses 878M Real-World Smell And Chemical Data Points, Primarily Generated From Semiconductor Manufacturing And Real-World Operating Environments 
Ainos Notes Review Of Its One-Year, AI-Analyzed Breath Pattern Study Focusing On Chronic Obstructive Pulmonary Disease 
Ainos, Inc. (NASDAQ:AIMDW) Sees Significant Decrease in Short Interest - Ainos Activates Phased Industrial Deployment Roadmap To Install Up To 20K AI Nose Units
Ainos And Trusval Technology Agree To Establish Distribution And Deployment Partnership Within Defined Scope Of Semiconductor Front-End Manufacturing Applications - Ainos Collaborates With NEXCOM International To Integrate Ainos' AI Nose Technology With NEXCOM's Industrial Edge Computing Platforms
Your note
Sign in to keep a note on AIMDW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| CVI Holdings, LLC | 10.58% | 82,500 | 2.41K | Jun 29, 2024 |
| Heights Capital Management, Inc | 10.58% | 82,500 | 2.41K | Sep 29, 2024 |
| Citadel Advisors Llc | 5.99% | 46,717 | 1.36K | Sep 29, 2024 |
| Boothbay Fund Management, LLC | 3.21% | 25,000 | 730 | Sep 29, 2024 |
| Warberg Asset Management LLC | 2.41% | 18,800 | 548 | Sep 29, 2024 |
| Flow Traders U.S. LLC | 1.37% | 10,675 | 311 | Sep 29, 2024 |